Co-Diagnostics Stock Surges 630% in Six Days on Ebola PCR Test Expansion
CODX•Co-Diagnostics shares jumped nearly 80% in a single session, extending a six-day rally that has lifted the stock over 630% following expansion of its Polymerase Chain Reaction test program for the Bundibugyo Ebola strain. The company and its Indian joint venture CoSara Diagnostics aim to accelerate international deployment and develop both strain-specific and pan-Ebola assays.
1. Rapid Share Rally
Co-Diagnostics stock has soared over 630% in six trading sessions, including an 80% jump on the latest session, marking the largest monthly advance since its 1-for-30 reverse split in January. Retail investors and diagnostics sector speculators have driven heavy volume amid heightened Ebola concerns.
2. Expanded PCR Test Program
The company announced an expansion of its PCR-based diagnostics to include Bundibugyo-specific and pan-Ebola configurations. This program targets multiple Ebola virus strains, positioning Co-Diagnostics for broad outbreak detection capabilities.
3. Joint Venture Deployment
In collaboration with its Indian joint venture CoSara Diagnostics, Co-Diagnostics plans to scale production and expedite international distribution if the Ebola outbreak worsens. The partnership aims to deploy both laboratory and potential point-of-care testing solutions in affected regions.
4. Outbreak Context
The current Ebola outbreak in the Democratic Republic of Congo and Uganda has generated over 900 suspected cases and 223 suspected deaths. Global health agencies, including the WHO and CDC, have intensified screening and surveillance, underscoring urgent demand for rapid diagnostics.
